NASDAQ: PMVP - PMV Pharmaceuticals, Inc.

Yield per half year: -18.52%
Dividend yield: 0.00%
Sector: Healthcare

Share chart PMV Pharmaceuticals, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc., прецизионная онкологическая компания, открытие и разработка маломолекулярных, опухолеагностических методов лечения мутаций р53 при раке. Его ведущим продуктом-кандидатом является PC14586, небольшая молекула, которая корректирует и восстанавливает функцию р53. Компания также разрабатывает продукты-кандидаты для мутации точки доступа p53 R273H и других мутаций точки доступа p53. PMV Pharmaceuticals, Inc. ранее была известна как PJ Pharmaceuticals, Inc. и изменена на в июле 2013 года. Компания была основана в 2013 году со штаб-квартирой в Крэнбери, штат Нью-Джерси.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2020-09-25
ISIN US69353Y1038
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт http://www.pmvpharma.com
Цена ао 1.21
Change price per day: 0% (1.21)
Change price per week: -5.47% (1.28)
Change price per month: -15.38% (1.43)
Change price per 3 month: -17.69% (1.47)
Change price per half year: -18.52% (1.485)
Change price per year: -26.67% (1.65)
Change price per 3 year: -94.44% (21.77)
Change price per year to date: -19.33% (1.5)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0.4423 10
P/E 6.09 10
EV/EBITDA -0.447 0
Total: 6.13

Efficiency

Title Value Grade
ROA, % -26.48 0
ROE, % -29.23 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0139 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 144.84 10
Yield EPS, % -52.57 0
Total: 5
More

Institutions Volume Share, %
Orbimed Advisors LLC. 6475291 12.59
JP Morgan Chase & Company 3930340 7.64
Blackrock Inc. 3229797 6.28
ArrowMark Colorado Holdings LLC 2714143 5.28
Euclidean Capital LLC 2627643 5.11
Vanguard Group Inc 2405307 4.68
Alkeon Capital Management LLC 2345361 4.56
Woodline Partners LP 1791553 3.48
Interwest Venture Management Co. 1614911 3.14
Verition Fund Management, LLC 1580487 3.07

ETFShare, %Profitability for 1 year, %Dividends, %
iShares Micro-Cap ETF 0.01681 17.09 1.54048
Schwab U.S. Small-Cap ETF 0.00152 17.47 1.51433
0.0117.281.52



Head Job title Payment Year of birth
Dr. Arnold J. Levine Ph.D. Co-Founder, Director & Member of Scientific Advisory Board 140k 1940 (85 years)
Mr. Robert Ticktin General Counsel, Head of Operations & Company Secretary N/A 1962 (63 years)
Dr. David H. Mack Ph.D. Co-Founder, CEO, President & Director 762.02k 1962 (63 years)
Mr. Tim Smith Senior VP and Head of Corporate Development & Investor Relations N/A
Dr. Binh Vu Ph.D. Senior Vice President of Drug Discovery & CMC N/A
Ms. Crystal Zuckerman Vice President of Human Resources N/A
Mr. Michael Carulli Chief Financial Officer N/A 1974 (51 year)
Dr. Deepika Jalota Pharm.D. Chief Development Officer 1977 (48 years)
Dr. Marc Fellous M.D. Senior VP and Head of Clinical Development & Medical Affairs
Ms. Laura De Leon VP & Head of Clinical Operations

Address: United States, Cranbury, NJ , 8 Clarke Drive - open in Google maps, open in Yandex maps
Website: http://www.pmvpharma.com